SELLAS Life Sciences (SLS) Accumulated Expenses (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Accumulated Expenses data on file, last reported at $2.3 million in Q1 2026.

• Quarterly Accumulated Expenses fell 12.06% year-over-year to $2.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 million (down 12.06% YoY) and the FY2025 annual result came in at $3.5 million, down 35.51% from the prior year.
• Accumulated Expenses slipped to $2.3 million in Q1 2026 per SLS's latest filing, from $3.5 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $7.6 million in Q4 2023 and bottomed at $2.1 million in Q2 2025.
• The 5-year median for Accumulated Expenses is $5.2 million (2024), against an average of $4.7 million.
• The widest annual swing landed in 2022, when Accumulated Expenses surged 138.11%; it then plunged 60.7% in 2025.
• Tracing SLS's Accumulated Expenses over 5 years: stood at $6.3 million in 2022, then advanced by 21.7% to $7.6 million in 2023, then retreated by 28.55% to $5.5 million in 2024, then sank by 35.51% to $3.5 million in 2025, then tumbled by 35.86% to $2.3 million in 2026.
• Per Business Quant, the three latest SLS Accumulated Expenses figures stand at $2.3 million (Q1 2026), $3.5 million (Q4 2025), and $3.0 million (Q3 2025).

Peer Comparison